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Background: Meprin displays multiple functions in both health and disease, due in part to its broad proteolytic
activity. In this report, we explored the clinical significance and functional relevance of the expression of meprin-ɑ
(MEP1A) in colorectal cancer (CRC).
Methods: The mRNA and protein expression levels of MEP1A in tumor specimens obtained from CRC patients was
determined by quantitative real-time PCR and Western blot assay and comparatively paired with adjacent mucosa
that presented as normal tissue. ShRNA was used to knock-down MEP1A expression in CRC cell-lines and the
effects of dampened expression of MEP1A on the proliferation and invasion were determined by colony formation
assays, Cell Counting Kit-8 assays and matrigel invasion assays. Moreover, nude mouse xenograft models were
designed to investigate the same effect in vivo. In order to determine whether MEP1A expression correlated with
CRC clinicopathologic factors and survival, immunohistochemical staining of a tissue microarray containing 88
paired CRC specimens was performed.
Results: In CRC, enhanced expression of MEP1A was seen. Additionally, both in vitro and in vivo, CRC cellular
proliferation and invasiveness was inhibited by dampened MEP1A expression. Several parameters were associated
with enhanced MEP1A expression including tumor size (P = 0.023), staging of CRC by the American Joint
Committee on Cancer (AJCC) (P = 0.024), and T (P = 0.032) and N stages (P = 0.001). Moreover, the expression of
MEP1A is an independent prognostic factor for overall survival in CRC (HR 3.643; 95 % CI 0.305-5.842; P = 0.007).
Conclusion: MEP1A was not only found to be functionally important, but it might also serve as an important and
unique indicator of patient prognosis and therapeutic targeting in CRC.
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Colorectal cancer (CRC) is highly prevalent globally with
new cases reportedly exceeding 100,000 annually [1]. Al-
though surgical and adjuvant treatment approaches have
improved, malignancy-associated long-term survival
remains unsatisfactory because of the recurrence and
metastasis of the original tumor [2, 3]. A clinically
important objective is the identification of functionally* Correspondence: pzh_sjtu@163.com
1Department of General Surgery, First People’s Hospital, Shanghai Jiao Tong
Univerisity, 85 Wujin Road, Shanghai 200080, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeimportant genes in CRC development and progression,
and their utility in prognostic prediction.
Meprin is a member of the astacin family and a zinc
metalloendopeptidase that was initially discovered as a
protease that was highly expressed at kidney brush
border membranes [4] and intestinal epithelial cells [5].
Meprin is comprised of two homologous subunit do-
mains that include the meprin-α (MEP1A) domain and
the meprin-β (MEP1B) domain that share 42 % identity
in their amino acid sequence.
The broad proteolytic activity of meprin in health and
disease displays many functions. Thus, meprin is linkedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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MEP1A expression is differentially associated with colo-
rectal, breast, osteosarcoma, among other cancer types,
and pancreatic cell-lines [9, 10]. Furthermore, MEP1A is
aberrantly secreted to the stroma in the setting of CRC
[6]. Additionally, human prostate cancer cell models,
also expressed MEP1A where it promoted cellular rep-
lication and invasiveness [11]. However, in cancer, the
precise substrates and pathogenic role of meprins re-
mains unresolved.
In the current report, we aimed to study the expres-
sion and clinical significance of MEP1A in CRC. This
was achieved by determining MEP1A expression in CRC
specimens, and paired comparative analysis to adjacent
normal mucosal tissues. Next, by knocking down
MEP1A expression with small hairpin RNA (shRNA),
we studied functional relevance of MEP1A expression
on in vitro and in vivo cellular proliferation and invasion
in CRC. Moreover, we studied associations between
MEP1A expression, the clinico-pathological features of
CRC, and patient survival outcomes by immunohisto-
chemical analysis of a CRC tissue microarray.
Methods
Patients and specimens
Collections of tissue specimens from 36 CRC patients
(i.e., 24 male and 12 female; median age, 61.3 years,
range 25–86 years) that had undergone tumor resection
without chemotherapy or radiotherapy before surgery
were conducted between October 2014 and April 2015
at the General Department of Surgery at Shanghai Jiao
Tong University Affiliated Shanghai First People’s Hos-
pital (China). Two pathologists confirmed the diagnoses
and performed tumor staging according to the guidelines
of the American Joint Committee on Cancer (AJCC). All
CRC and paired adjacent normal mucosal specimens
were collected in the General Surgery Department by
protocols that were approved by the Institutional Review
Boards of Shanghai Jiao Tong University Affiliated
Shanghai First People’s Hospital Medical Center. Writ-
ten and informed consent was provided by all patients
for study participation. The freshly obtained cancer tis-
sues and adjacent normal mucosa located 10 cm from
the original tumor site were then immediately cryopre-
served in liquid nitrogen and archived at −80 °C prior to
RNA and protein extraction.
Cell-lines and reagents
LoVo, Caco2, RKO and HT29 cells are established
CRC cell-lines, and were obtained from the Type Cul-
ture Collection of the Chinese Academy of Sciences
(Shanghai, China). The healthy human colonic mucosal
cell-line, NCM460, was obtained from INCELL (San
Antonio, TX, USA). All cell-lines were cultured in afully humidified atmosphere of 5 % CO2 in air at 37 °C.
Cell-lines were cultured in DMEM/F12 culture media
that was supplemented with 10 % FBS (Gibco, USA),
100 U/mL penicillin and 100 mg/L streptomycin.Establishing MEP1A-KD cell-lines
Commercially available MEP1A shRNA constructs
(Genechem Co. Ltd., Shanghai, China) were used to






LoVo and Caco2 cells were transduced with 5 × 105
transducing units/mL of lentiviral particles. Antibiotic
selection (1 μg/mL puromycin) was initiated for 7 days
at 24 h immediately after transduction. Consequently,
LoVo-sh-MEP1A and Caco2-sh-MEP1A were generated.
Cells that were transduced with sh-control (LoVo-sh-
control and Caco2-sh-control) were used as controls.RNA extraction, reverse transcription PCR and
quantitative real-time PCR
Total RNA was prepared from cell cultures, fresh pri-
mary tumors and normal mucosa of 36 CRC patients by
the TRIzol reagent procedure (TaKaRa, Japan) in accord-
ance with the manufacturer’s instructions. Using total
RNA at 2 μg, first strand cDNA was synthesized by
using the RevertAid™ First Strand cDNA Synthesis Kit,
and following the procedures according to the manufac-
turer’s instructions (Fermentas, USA). To enable reverse
transcription PCR, the following PCR conditions were
employed: 30 cycles of 94 °C for 1 min, 55 °C for 1 min,
72 °C for 1 min, and a final extension step at 72 °C for
10 min. Next, 10 μl of the PCR-derived amplicon was
resolved by 1 % agarose gel electrophoresis and counter-
staining by ethidium bromide (EtBr), with resolved bands
quantified by Quantity One software (Bio-Rad, USA).
Quantitative real-time PCR (qRTPCR) assays were
performed using 4 μl of cDNA (at a dilution of 1:10)
and SYBR green (TaKaRa) in a final volume of 20 μl
using the ABI 7900 Real-time PCR System (ABI,
USA). The amplification protocol used the following
conditions: 95 °C for 2 min, and then 95 °C for 10 s,
60 °C for 30 s, and 72 °C for 30 s, with a final exten-
sion at 72 °C for 30 s. Relative quantities of the PCR
amplicons were determined by normalizing to
GAPDH using the Δ cycle threshold (Ct) values. Each
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and anti-sense 5’-ATGTGGGGCAGAGAGATGAC-3’;
PCNA, sense 5’- CTTCCCGCCGTCCTGTAGC -3’
and anti-sense 5’-CTCCTTCTGCACACATTTGAA-3’;
Ki67, sense 5’-TTCGCAAGCGCATAACCCA-3’ and
anti-sense 5’-GCCGGCGCATTTTAGTATTTTG-3’.
Western blot assays
A RIPA lysis buffer (Beyotime Biotechnology, China)
was used to isolate total protein from tissue samples or
cultured cells and the BCA protein assay kit (Beyotime
Biotechnology) determined total protein concentrations.
Equal concentrations of isolated protein (i.e., at 30 μg)
were resolved through 10 % sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
electro-transferred to a PVDF membrane, which was
then blocked for 1 h at room temperature in a 5 % fat-
free milk proteins solution that was supplemented with
0.1 % Tween-20. Membranes were reacted with a pri-
mary detection antibody (1:500 dilution for MEP1A,
R&D Systems, USA and 1:1,000 dilution for GAPDH,
Abgent, USA) at 4 °C overnight followed by cross-
reaction for 2 h at room temperature with a secondary
detection antibody (1:5,000, Abgent) that was directed
against goat/rabbit IgG-HRP. To detect cross-reacted
proteins, we used an enhanced chemiluminescence
(ECL) reagent (Pierce Biotechnology, USA). Quantifica-
tion by grayscale analysis was performed by employing
Quantity One software program analysis (Bio-Rad, USA).
Plate colony-forming assays and CCK-8 assays
The plate colony-forming assay measures cell prolifera-
tion, and follows the recommendations set out in the
manufacturer’s instructions. Briefly, 800 log-phase cells
were seeded into six-well tissue culture plates then
subsequently incubated at 37 °C under a fully humidi-
fied atmosphere of 5 % CO2 in air for two weeks. Cells
were then fixed for 15 min in methanol and stained
with Giemsa solution for 20 min. Colonies were then
counted and images recorded by standard photography.
Independent assays were performed in triplicate. For
Cell Counting Kit-8 (CCK-8), cells were seeded in trip-
licate into 96-well microtiter plates at a density of 2 ×
103 cells/well. At appropriate time-points (i.e., 12, 24,
36, 48 h), cells were incubated with CCK-8 reagent
(10 μl) for 2 h at 37 °C. Absorbance values were deter-
mined at a wavelength of 450 nm using a Gen5 micro-
plate reader (BioTek, USA).
Scratch assays
Cells were plated in six-well dishes and the scratch assay
was conducted. In this assay, LoVo cells were incubated in
endothelial cell culture medium that was supplemented
with 5 % FBS. When cells had achieved 80 % confluence, ascratch was made across the adherent cultured cells using
a sterile plastic micropipette tip that provoked a single
homogeneous wound along each well, following which,
displaced cells were removed by two PBS washes. Cells
were cultured for 36 h and microscopic images were re-
corded using an ocular grid. Three wounds were samples
for each treatment. The relative wound area was calcu-
lated as previously described [12].
Matrigel invasion assays
For this procedure, 24-well Transwell plates with pore
diameters of 8 μm (Corning, New York, NY, USA) were
pre-coated with a Matrigel matrix (BD Biosciences, San
Diego, CA, USA), following which 1 × 105 transfected
LoVo cells were suspended in 200 μL of 1 % FBS supple-
mented RMPI 1640 media, and then seeded to the upper
compartment of each inserted well.
Normal growth medium that was supplemented with
10 % FBS, was then added to the lower wells. Cells were
allowed to migrate for 48 h at 37 °C, following which,
those that had migrated were fixed for 5 min in 10 %
methanol and then air dried at room temperature. The
invaded cells that were present on the lower surface of
the membrane were stained with 2 % crystal violet for
5 min, and then scored by visual inspection and standard
light microscopy. To minimize bias, at least five independ-
ent fields of view at × 100 magnification were scored fol-
lowing which, the aggregated counts were averaged.
Nude mouse xenograft models
Xenografts of CRC were established in male BALB/C
nude mice (aged 4-weeks) that were provided by the
Institute of Zoology, Chinese Academy of Sciences of
Shanghai. Briefly, Luciferase tagged sh-MEP1A and sh-
control LoVo cells were suspended in 100 μL of PBS at
a density of 3 × 106 and adoptively transferred to the
above described recipient mice. Half of the mice were
subcutaneously adoptively transferred and the remain-
der were adoptively transferred through the lateral tail
vein. Following anesthesia, mice were treated at weekly
intervals with D-luciferin (150 mg/kg) by i.p. injection,
and imaged 10 min later by an IVIS Illumina System
(Caliper Life Sciences). Ten weeks after the tail vein
injection, mice were euthanized and examined for the
presence of both subcutaneous tumors and lung metas-
tases. All animal procedures strictly followed the
Shanghai Jiao Tong University Affiliated Shanghai First
People’s Hospital Animal Care and Use Guidelines. All
humane efforts were made to minimize animal suffering.
Immunohistochemistry on tissue microarrays
Since the 36 paired tissue specimens were collected only
one year ago and their follow-up data was lacked, we
chose to use a tissue microarray (TMA) with an over
Wang et al. BMC Cancer  (2016) 16:383 Page 4 of 125 years’ follow-up data and a detailed clinico-pathological
data to determine whether MEP1A expression correlated
with CRC clinico-pathological factors and survival. The
TMA containing 88 paired CRC specimens was obtained
from the Xin Chao Company (Shanghai, China). Tumors
were resected between July 2006 and May 2007, with a
final follow-up of August 2012. In surviving patients, the
median follow-up time was 46.62 months, and a range of
3–73 months. Samples were obtained from 46 male and
42 female patients with a mean age of 68.72 years; range,
24–90 years. Tumor staging was completed by following
the AJCC staging criteria [13]. Detailed information on




<65 31 13 18
≥65 57 24 33
Gender
Male 46 18 28
Female 42 19 23
Location
Right 37 15 22
Others 51 22 29
Tumor size (cm)
<5 47 25 22
≥5 41 12 29
AJCC stage
I + II 52 27 25
III + IV 36 10 26
T stage
T1 + T2 9 7 2
T3 + T4 79 30 49
N stage
N0 54 30 24
N1 + N2 34 7 27
M stage
M0 86 37 49
M1 2 0 2
Differentiation
Well + Moderate 78 35 43
Poor 10 2 8
Vascular invasion
No 84 37 47
Yes 4 0 4
Immunohistochemistry on tissue microarrays containing 88 paired CRC specimens w
Key: *indicates P < 0.05. a Chi-square test. b Fisher’s exact test(Table 1). Dewaxing of sections by xylene treatment was
followed by rehydrating specimens in a graded series of
ethanol concentrations followed by antigen retrieval with
0.01 M sodium citrate buffer (pH 6.0).
A MEP1A-specific primary antibody (at a dilution of
1:200; R&D Systems Inc, USA) or an E-cadherin specific
primary antibody (1:100; Santa Cruz, USA) was used for
immuno-histochemical staining assays. Primary antibody
staining was immediately followed by detection with an
HRP-conjugated secondary antibody (Dako Cytomation,
Glostrup, Denmark). Two specialists blinded to patient
outcome provided independent evaluation of the staining.




0.988a 39 18 0.120a
29 17
0.562a 26 16 0.912a
21 16
0.808a 34 17 0.343a
31 16
0.023*a 24 17 0.473a
26 26
0.024*a 29 7 0.004*a
6 3
0.032*b 49 30 1.000b
29 25
0.001*a 26 8 0.032*a
53 33
0.507b 2 0 0.526b
51 27
0.182b 4 6 0.167b
51 33
0.135b 4 0 0.292b
as performed and more specific information was given in ‘Methods’
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described here: 0 (negative), 1 (weak), 2 (moderate), and 3
(strong). The extent of staining was scored as 0 (0 %), 1
(1–25 %), 2 (26–50 %), 3 (51–75 %), and 4 (76–100 %) ac-
cording to the percent frequency of positively stained cells.
Additionally, multiplying the scores of the staining inten-
sity with that of the extent of staining gave “the final stain-
ing score.” According to the final scores, two groups were
derived; i.e., 1) a low scoring group (0–6), and 2) a group
that scored high (7–12).
Statistical analysis
The Student’s two-tailed T-test determined the statistical
significance of in vitro and in vivo data. In addition, the
two-tailed χ2 test and Fisher’s exact test determined the
statistical significance of covariate differences. The Kaplan–Fig. 1 Expression of MEP1A in human colorectal cancer tissues and cell-lin
compared with normal samples. Fold change was calculated by 2-ΔΔCT me
was significantly higher than paired adjacent normal mucosa specimens (b
tumor tissues (c). MEP1A protein is higher expressed in tumor tissues than
colorectal cell-lines. Grayscale values were evaluated (n = 3, * p < 0.05, comMeier method determined patient survival rates, and com-
parisons of survival curves was done using the log-rank
test. For experimental variables, the Cox proportional haz-
ards model was used to determine multivariate Hazard
Ratios (HRs). An alpha value of P <0.05 was considered a
statistically significant difference. All statistical analyses
were determined by the SPSS version 19.0 statistical soft-
ware package (SPSS Inc., Chicago, IL, USA).
Results
Aberrant MEP1A over-expression in CRC tissues
Of the 36 randomly selected paired cases that were
assessed for mRNA and protein expression of MEP1A,
23 (64 %) cases of CRC displayed at least a two-fold in-
crease in MEP1A mRNA levels as compared their adja-
cent non-malignant tissue counterparts (Fig. 1a). The meanes. Relative expression of MEP1A mRNA in 36 paired tumorous samples
thod (a). The mean MEP1A mRNA expression in these 36 tumor tissues
). Western blot analysis of MEP1A expression in seven paired colorectal
in paired adjacent normal mucosa (d). MEP1A protein expression in five
pared with NCM460 cell-line) (e)
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was significantly higher than which in paired adjacent nor-
mal mucosal specimens (i.e., 1.04 ± 0.04 vs. 0.49 ± 0.03, re-
spectively at P < 0.001 by Student’s t-test; Fig. 1b).
Subsequent Western blotting analysis confirmed that the
protein expression levels of MEP1A were also higher inFig. 2 MEP1A knock-down inhibits colorectal cancer cell proliferation. Wes
Caco2 and LoVo cell-lines. Grayscale values were evaluated (n = 3, * p < 0.0
knock-down cells according to real-time PCR analysis (n = 3, * p < 0.05) (b).
colony formation assays (c) and Cell Counting Kit-8 assays (d) (n = 3, * p < 0CRC specimens than were found in the matched ad-
jacent non-tumor tissues (i.e., 1.04 ± 0.05 vs. 0.47 ±
0.03 at P < 0.001, Student’s t-test; Fig. 1c-d). Protein
expression of MEP1A in Caco2 and LoVo cells
exceeded that found in NCM460 cells (Fig. 1e), which
suggested enhanced expression of MEP1A in CRC.tern blot analysis of MEP1A protein expression in stable knock-down
5) (a). Expression of proliferation-related genes was inhibited in MEP1A
Effects of MEP1A knock-down on cell growth was evaluated by plate
.05)
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proliferation in vitro
Knock-down of MEP1A expression in transfected
Caco2 and LoVo cell-lines was achieved by an MEP1A-
shRNA procedure with the goal of exploring how
MEP1A expression influences CRC cell proliferation.
Western blot assays confirmed the efficiency of MEP1A
knock-down (Fig. 2a). In addition, quantitative PCR
detected the expression of the proliferation-related
genes PCNA and Ki67 to determine the effects of
MEP1A knock-down on CRC cell proliferation (Fig. 2b).
PCNA and Ki-67 mRNA expression was down-regulated
in sh-MEP1A cells (P < 0.01). Next, the colony formation
and CCK-8 assay were used to determine cell colony
forming ability and viability (Fig. 2c, d). Knocking
down MEP1A expression in CRC cells consistently
dampened colony forming ability as compared sh-control
cells (P < 0.01). Furthermore, MEP1A knock-down was
associated with significantly decreased cellular prolif-
eration as compared with cells that were transfected
with control-shRNA (Fig. 2d). These observations
suggested a critical role for MEP1A in CRC cellular
proliferation.Fig. 3 MEP1A knock-down inhibits colorectal cancer cell migration and inv
knock-down LoVo cells had less migration ability (a) and invasion ability (b
injury. The results represent mean ± SD of at least 12 wounds and were anDampened MEP1A expression decreases CRC cell
migration and invasion in vitro
To determine the effects of knocking down MEP1A
expression on migration and invasion of CRC cells,
scratch and matrigel invasion assays were performed
using LoVo cells (Fig. 4a and b). The migration of cells
into the scratch region was reduced in MEP1A knocked-
down LoVo cells (Fig. 3a). Knock-down of the MEP1A
protein resulted in a 51.35 % reduction in the invasive
ability of LoVo cells (i.e., 72 ± 6 vs. 148 ± 16; cells per
field; Fig. 3b). These results indicated that CRC cellular
migration and invasion in vitro might be potently aug-
mented by functional MEP1A expression.
MEP1A knock-down represses CRC growth and metastasis
in vivo
Taking the above observation into account, we determined
the tumorigenicity of sh-MEP1A and sh-control LoVo
cells when adoptively transferred by subcutaneous or lat-
eral tail vein injection into nude mice. All mice survived
the procedure and appeared healthy. Formation of tumors
was determined by longitudinal in vivo imaging of LoVo
cells that stably expressed a luciferase marker gene for aasion. Scratch assays and matrigel invasion assays showed that MEP1A
) than control LoVo cells. The wound areas were measured 36 h post
alyzed by the Student’s t-test (* p < 0.05)
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tively transferred with sh-MEP1A cells exhibited latent
tumor morbidity and blunted tumor growth in both the
subcutaneous and the tail vein injection groups as com-
pared mice that were adoptively transferred with sh-
control cells. These in vivo data were consistent with the
in vitro results, and confirmed that MEP1A knock-down
repressed CRC growth and metastasis.
Correlation between MEP1A expression and
clinicopathologic factors in CRC
MEP1A and E-cadherin expression was determined by
immunohistochemical analysis of a TMA containing 88
CRC specimens and paired adjacent normal mucosa.
Membrane-restricted expression of MEP1A was seen
with negligible extracellular staining, while E-cadherin
expression was restricted to the membrane (Fig. 5a). Tu-
mors showed variable (i.e., weak, moderate, and strong)
MEP1A expression. A high level of MEP1A expression
was detected in 51 of 88 CRC specimens. AssociationsFig. 4 MEP1A knock-down repress colorectal cancer growth and metastasi
106) were injected into the 4-week-old nude mice. Half of the mice were su
and the remainder were injected by lateral tail vein (Control-T and MEP1A-KD
signals (a) and photon flux (b) are shown (* p < 0.05)of MEP1A and E-cadherin expression with clinicopath-
ological factors are shown (Table 1). High expression
of MEP1A was significantly correlated with tumor size
(P = 0.023), AJCC stage (P = 0.024), T stage (P = 0.032)
and N stage (P = 0.001). Low E-cadherin expression
(i.e., in 55 of 88 specimens) was markedly associated
with AJCC stage (P = 0.004) and N stage (P = 0.032). In
most cases, tumors with high MEP1A expression
showed low E-cadherin expression. A negative correl-
ation shown between expression of MEP1A and E-
cadherin was identified by Spearman’s rank correlation
coefficient (P < 0.001; Table 2).
MEP1A or E-cadherin expression – Analysis of survival
and prognosis
Kaplan-Meier analysis with a log rank test for overall
survival (OS) determined possible associations between
tumor expression of MEP1A and patient survival
(Fig. 5b). Patients that displayed high levels of MEP1A
expression in their tumor had a poorer OS (P < 0.001)s in vivo. Luciferase tagged sh-control and MEP1A-KD LoVo cells (3 ×
bcutaneously injected (Control-S and MEP1A-KD-S, 5 mice each group)
-T, 5 mice each group). All four groups’ representative images of luciferase
Table 2 The association between MEP1A and E-cadherin
expression
Tissue sample E-cadherin expression P value r
Low High
MEP1A Low 14 23
MEP1A High 41 10 <0.001 −0.43
Fig. 5 Immunohistochemical staining in colorectal cancer and Kaplan-Meier plots with log rank test of overall survival (OS). Adjacent normal
mucosa showing very weak MEP1A staining (upper left, 200×), and high staining of MEP1A (upper right, 200×) in a moderately differentiated
colon tumor. On the contrary, E-cadherin showing high expression in normal mucosa (lower left, 200×) while very weak staining in poorly
differentiated tumor tissue (lower right, 200×) (a). Overall survival of 88 patients in relation to MEP1A expression levels as determined by
immunohistochemical staining of tissue microarrays. OS was significantly lower in patients with tumors that expressed high levels of MEP1A as
compared patients with tumors that expressed low levels of MEP1A (b)
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Using a univariate analysis in the Cox proportional
hazards model, a decreased OS was associated with the
following characteristics: tumor location, AJCC stage,
LNM stage, distant metastasis, vascular invasion and
the expression of MEP1A and E-cadherin (Table 3). The
expression of MEP1A was an independent prognostic
Table 3 Univariate and multivariate analysis of overall survival
Univariate analysis Multivariate analysis
HR (95 % CI) P value HR (95 % CI) P value
Age
<65 1
≥65 1.350 (0.706-2.581) 0.364
Gender
Male 1
Female 0.910 (0.503-1.648) 0.756
Location
Right 1 1
Others 0.470 (0.259-0.852) 0.013* 0.666 (0.335-1.323) 0.246
Tumor size (cm)
<5 1
≥5 1.801 (0.993-3.267) 0.053
AJCC stage
I + II 1 1
III + IV 3.106 (1.701-5.671) <0.001* 1.335 (0.305-5.842) 0.701
T stage
T1 + T2 1
T3 + T4 1.662 (0.514-5.370) 0.396
N stage
N0 1 1
N1 + N2 3.106 (1.701-5.671) <0.001* 2.129 (0.468-9.686) 0.328
M stage
M0 1 1
M1 10.801 (2.448-47.658) 0.002* 14.382 (1.059-195.249) 0.045*
Differentiation
Well + Moderate 1
Poor 2.026 (0.627-6.548) 0.238
Vascular invasion
No 1 1
Yes 6.188 (2.093-18.295) <0.001* 1.190 (0.264-5.366) 0.821
MEP1A
Low 1 1
High 5.977 (2.651-13.478) <0.001* 3.643 (0.305-5.842) 0.007*
E-cadherin
Low 1 1
High 0.425 (0.215-0.842) 0.014* 0.605 (0.252-1.453) 0.261
Key: *indicates P < 0.05
Wang et al. BMC Cancer  (2016) 16:383 Page 10 of 12factor for OS as determined by multivariate analysis (i.e.,
HR 3.643; 95 % CI 0.305-5.842; P = 0.007).
Discussion
The involvement of the metalloprotease MEP1A in
multiple cancers was previously shown [14]. However,
studies on MEP1A expression during tumorigenesis andprogression of CRC are rare and the molecular mecha-
nisms that implicate involvement of MEP1A in CRC
remain unclear.
For the first time, the current study showed that mRNA
and protein expression of MEP1A were increased in pri-
mary CRC tissues. Immunohistochemistry showed that
high MEP1A expression in CRC tissues was significantly
Wang et al. BMC Cancer  (2016) 16:383 Page 11 of 12aligned to other features of the malignant tumor. These
characteristics included tumor size, AJCC stage, tumor
depth, and lymph node metastasis, which suggested that
expression of MEP1A might serve as a CRC biomarker.
E-cadherin is a transmembrane glycoprotein and the
major structural component of adherent junctions of the
epithelium that mediate homotypic interactions between
adjacent cells that are calcium-dependent. In cancer, de-
creased E-cadherin expression is functionally important
in the progression of well-differentiated adenoma to in-
vasive carcinoma [15], Moreover, E-cadherin might thus
serve as a tumor suppressor [16].
In this immunohistochemical study, we found that high
MEP1A expression correlated negatively with E-cadherin
expression, suggesting that MEP1A is involved in tumor
migration and invasion. To confirm this hypothesis,
scratch and matrigel invasion assays revealed decreased
migration and invasion of LoVo cells in the sh-MEP1A
group as compared their control group counterparts.
Studying the effects of MEP1A on CRC cell prolifera-
tion in CCK-8 assays revealed that MEP1A knock-down
in Caco2 and LoVo cells inhibited their proliferation.
Moreover, we noted significantly reduced colony forma-
tion in MEP1A knock-down cells. These data collectively
suggested that suppressed MEP1A expression blocked
cell proliferation and further implied specific therapeutic
targeting of MEP1A in the setting of CRC.
Based on these in vitro findings, we proceeded to inves-
tigate the tumorigenicity of sh-MEP1A and sh-control
cells. As anticipated, down-regulation of MEP1A sup-
pressed both subcutaneous and metastatic tumor forma-
tion in nude mice. These in vivo data were consistent with
observation made in vitro, and confirmed that MEP1A
knock-down inhibited CRC growth and invasion.
The potential utility of MEP1A expression as a
prognostic marker in CRC has not been previously
reported. In this report, Kaplan-Meier survival ana-
lysis demonstrated that high MEP1A expression was
significantly related to poor prognosis that is com-
monly seen in CRC patients following surgical resec-
tion (P < 0.001). In our study, patients with elevated
MEP1A expression were significantly linked to a
poorer OS outcome. Furthermore, MEP1A expression
was suggested as an independent prognostic factor by
Cox regression analysis. These observations suggested
that MEP1A might uniquely offer prognostic predic-
tion in the setting of CRC.
It should be noted that there are some limitations of
our study. First, there might be a potential selection bias
for only patients who had undergone tumor resection
without chemotherapy or radiotherapy were included in
the mRNA and protein expression study. Second,
MEP1A overexpressing cell lines were not investigated
in our study in the present day. Third, further studiesare required to confirm MEP1A/E-cadherin association
and our hypothesis that MEP1A is a potential thera-
peutic target for CRC.
Conclusions
We conclude that MEP1A played a functionally crucial
role in CRC carcinogenesis, which was particularly evi-
dent in terms of tumor proliferation and invasion. For
the first time, we show that MEP1A expression was ele-
vated in CRC tissues at both the mRNA and protein
levels. Furthermore, cell proliferation and invasion was
blocked when expression of MEP1A was knocked down
in CRC cells. Moreover, we confirmed a role for MEP1A
in CRC progression in relevant animal models. Finally,
we provided clinical evidence that suggested MEP1A
might serve as an independent prognostic indicator in
the setting of CRC outcomes.
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